Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2009
    In:  Journal of Clinical Oncology Vol. 27, No. 15_suppl ( 2009-05-20), p. 9053-9053
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 27, No. 15_suppl ( 2009-05-20), p. 9053-9053
    Abstract: 9053 Background: Cutaneous melanoma cells express a variety of cytokines and growth factors (C/GF) as the tumor progresses. This study was undertaken to identify various C/GF at different stages of the disease with the hope of identifying prognostic factors. Methods: Immunohistochemical (IHC) studies were performed on 62 specimens of parafinized human melanoma comprised of 12 primaries, 10 local recurrences, 6 intransit, 15 regional lymph node and 19 distant metastases. Staining for 17 C/GF was performed using commercially available antibodies on Bond-Max automated IHC system. Results: The overexpression of C/GF in primary lesions was compared to distant metastases with regard to intensity and extent of staining. Data was dichotomized as positive (dark staining) or negative (lesser or no staining). There was simultaneous intense staining of 4–15 C/GF in primaries and 3–14 C/GF in metastatic lesions. Comparing primaries to metastases by Chi-Square using Fisher's exact test, statistical differences were seen in intensities of transforming growth factor-β (p 〈 0.001), β-catenin (p 〈 0.01), Bcl-2 (p 〈 0.01). Staining intensities of IL-8 approached significance (p 〈 0.058). Statistical differences in extent of staining between primaries and metastases were found for insulin-like growth factor-1 (p 〈 0.01), fibroblast growth factor-basic (p 〈 0.05) and IL-15 (p 〈 0.05). Conclusions: Potential dynamic changes in overexpression or loss of expression of C/GF in metastatic melanoma is not clearly understood and may reflect on mutations. Melanoma is an extremely heterogeneous tumor and no single targeted therapeutic agent can control this disease. No significant financial relationships to disclose.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2009
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages